Risk factors for drug-induced liver disease

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 291-305

  DeLeve, Laurie D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012828315     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (167)

1. Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol 2005; 33:41-51.
2. Murata K, Sugimoto K, Hamada M. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by arylamine derivatives. Gastroenterology 2006; 130:A749.
3. Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explantation for high acetaminophen dosage in humans without hepatic injury. Hepatology 1999; 29:451-63.
4. Aleksunes LM, Scheffer GL, Jakowski AB, Pruimboom-Brees IM, Manautou JE. Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicantinduced injury. Toxicol Sci 2006; 89:370-9.
5. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manautou JE. Differential expression of hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 2005; 83:44-52.
6. Schenker S, Bay M. Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol 1994; 18:232-7.
7. Anonymous. National health and nutrition examination survey (NHANES III): Patterns of prescription drug use in the United States, 1988-1994. In; 1998, http//www.cdc.gov/nchs/data/nhanes/databriefs/preuse.pdf.
8. Kellaway GSM, McCrae E. Intensive monitoring for adverse drug effects in patients discharged from acute medical wards. NZ Med J 1973; 78:525-8.
9. May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977; 22:322-8.
10. Smith JW, Seidl LG, Cluff L. Studies on the epidemiology of adverse drug reactions. Ann Intern Med 1966; 65:629-40.
11. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing 1980; 9:73-80.
12. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (O70 years old) measured by means of iohexol clearance, serum creatinine, serum urea, and estimated clearance. Scand J Urol Nephrol 2004; 38:73-7.
13. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15:897-918.
14. Zoli M, Magalotti D, Bianchi G, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999; 28:29-33.
15. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34:359-73.
16. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9:297-301.
17. Veering BT, Burm AGL, Souverijn JHM, Serree JMP, Spierdijk J. The effect of age on serum concentrations of albumin and α1-acid glycoprotein. Br J Clin Pharmacol 1990; 29:201-6.
18. Lunde AV, Barrett-Connor E, Morton DJ. Serum albumin and bone mineral density in healthy older men and women: the Rancho Bernardo study. Osteoporos Int 1998; 8:547-51.
19. Kyle UG, Genton L, Hans D, et al. Total body mass, fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 60-year-old persons. J Am Geriatr Soc 2001; 49:1633-40.
20. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest 1999; 22:110-6.
21. Borkan GA, Hults DE, Gerzof SG, Burrows BA, Robbins AH. Relationships between computed tomography tissue areas, thicknesses and total body composition. Ann Hum Biol 1983; 10:537-45.
22. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306:1081-8.
23. Zamboni M, Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes 2005; 29:1011-29.
24. Chao C, Youssef J, Rezaiekhaleigh M, Birnbaum LS, Badr M. Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha. Mech Ageing Dev 2002; 123:1469-76.
25. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50:727-30.
26. Thomas RP, Guigneaux M, Wood T, Evers BM. Age-associated changes in gene expression patterns in the liver. J Gastrointest Surg 2002; 6:445-53 (discussion 454).
27. Agrawal AK, Shapiro BH. Constitutive and inducible hepatic cytochrome P450 isoforms in senescent male and female rats and response to low-dose phenobarbital. Drug Metab Dispos 2003; 31:612-9.
28. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74:275-87.
29. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44:33-60.
30. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44:239-42.
31. Cogger VC, Mross PE, Hosie MJ, Ansselin AD, McLean AJ, Le Couteur DG. The effect of acute oxidative stress on the ultrastructure of the perfused rat liver. Pharmacol Toxicol 2001; 89:306-11.
32. Le Couteur DG, Cogger VC, Markus AM, et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001; 33:537-43.
33. Le Couteur DG, Fraser R, Cogger VC, McLean AJ. Hepatic pseudocapillarisation and atherosclerosis in ageing. Lancet 2002; 359:1612-15.
34. Le Couteur DG, Hickey H, Harvey PJ, Gready J, McLean AJ. Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver. J Pharmacol Exp Ther 1999; 289:1553-8.
35. Harvey PJ, Gready JE, Yin Z, Le Couteur DG, McLean AJ. Acute oxygen supplementation restores markers of hepatocyte energy status and hypoxia in cirrhotic rats. J Pharmacol Exp Ther 2000; 293:641-5.
36. Grönhagen-Riska C, Hellstrom P-E, Fröseth B. Predisposing factors in hepatitis induced by isoniazid treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461-6.
37. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9:2026-30.
38. van den Brande P, van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152:1705-8.
39. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis prophylaxis. Role of biochemical monitoring in 1,000 patients. J Am Med Assoc 1979; 241:1239-41.
40. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77:335-40.
41. Duthie A, Nicholls A, Freeth M, Moorhead P, Triger D. Fatal cholestatic jaundice in elderly patients taking benoxaprofen [letter]. Br Med J 1982; 285:62.
42. Firth H, Wilcock GK, Esiri M. Side effects of benoxaprofen. Br Med J 1982; 284:1784.
43. Fisher BM, McArthur JD. Side effects of benoxaprofen. Br Med J 1982; 284:1783.
44. Goudie BM, Birnie GF, Wathinson G, MacSween RN, Kissen LH, Cunningham NE. Jaundice associated with the use of benoxaprofen. Lancet 1982; 1:959-1982.
45. Prescott LF, Leslie PJ. Side effects of benoxaprofen. Br Med J 1982; 284:1783.
46. Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J 1982; 284:1372.
47. Hamdy RC, Murnang B, Perera N, Woodcock K, Koch IM. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm 1982; 5:69-75.
48. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982; 2:591-7.
49. Konig SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update. Epilepsia 1994; 35:1005-15.
50. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379-85.
51. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. U.S. experience since 1984. Neurology 1989; 39:201-7.
52. Roe CM, McNamara AM, Motheral BR. Gender- and age-related prescription drug use patterns. Ann Pharmacother 2002; 36:30-9.
53. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Int Med 1992; 232:133-8.
54. Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. NZ Med J 1996; 109:315-9.
55. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Healthc 1994; 15:619-29.
56. Sagraves R, Raebel MA, Jermain DM, O’Connell MB, Wermeling DP. ACCP White Paper: women as research subjects. Pharmacotherapy 1993; 13:534-42.
57. Carney FMT, Van Dyke RA. Halothane hepatitis: a critical review. Anesth Anal 1972; 51:135-66.
58. Jenner MA, Plummer JL, Cousins MJ. Halothane reductive metabolism in an adult surgical population. Anaesth Intensive Care 1990; 18:395-9.
59. Martinez-Roig A, Cami J, Llorens-Terol J, de la Torre R, Perich F. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics 1986; 77:912-5.
60. Moult PJA, Sherlock S. Halothane-related hepatitis. A clinical study of twenty-six cases. QJMed 1975; 44:99-114.
61. Walton B, Simpson BR, Strunin L, Doniach D, Perrin J, Appleyard AJ. Unexplained hepatitis following halothane. Br Med J 1976; 1:1171-6.
62. Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154:311-6.
63. Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut 1992; 33:368-71.
64. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res 2001; 6:139-49.
65. Welch KD, Wen B, Goodlett DR, et al. Proteomic identification of potential susceptibility factors in drug-induced disease. Chem Res Toxicol 2005; 18:924-33.
66. Welch KD, Reilly TP, Bourdi M, et al. Genomic identification of potential risk factors during acetaminohen-induced liver disease in susceptible and resistant strains of mice. Chem Res Toxicol 2006; 19:223-33.
67. Coen M, Ruepp SU, Lindon JC, et al. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 2004; 35:93-105.
68. Coen M, Lenz EM, Nicholson JK, Wilson ID, Pognan F, Lindon JC. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol 2003; 16:295-303.
69. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440:1073-7.
70. Minami K, Saito T, Narahara M, et al. Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol Sci 2005; 87:296-305.
71. Reilly TP, Bourdi M, Brady JN, et al. Expression profiing of acetaminophen liver toxicity in mice using microarray technology. Biochem Biophys Res Commun 2001; 282:321-8.
72. Williams DP, Garcia-Allan C, Hanton G, et al. Time course toxicogenomic profiles in CD-1 mice after nontoxic and nonlethal hepatotoxic paracetamol administration. Chem Res Toxicol 2004; 17:1551-61.
73. Yamamoto T, Kikkawa R, Yamada H, Horii I. Identification of oxidative stress-related proteins for predictive screening of hepatotoxicity using a proteomic approach. J Toxicol Sci 2005; 30:213-27.
74. Devi SS, Mehendale HM. Microarray analysis of thioacetamide-treated type 1 diabetic rats. Toxicol Appl Pharmacol 2006; 212:69-78.
75. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82:1826-32.
76. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305:722-7.
77. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med 1989; 110:286-9.
78. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-84.
79. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49:13-17.
80. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 1991; 19:900-6.
81. Watson RGP, Olomu A, Clements D, Waring RH, Mitchell RH, Elias E. A proposed mechanism for chlorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol 1988; 7:72-8.
82. Chien JY, Peter RM, Nolan CM, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther 1997; 61:24-34.
83. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996; 15:394-405.
84. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99:465-71.
85. Jenner PJ, Ellard GA. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70:93-101.
86. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazide and rifampin. Am Rev Respir Dis 1986; 133:1072-5.
87. Rettenmeier AW, Prickett KS, Gordon WP, et al. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos 1985; 13:81-96.
88. Baillie TA. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem Res Toxicol 1988; 1:195-9.
89. Krahenbuhl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 1995; 37:140-3.
90. Ponchaut S, Van Hoof F, Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 1992; 43:2435-42.
91. Li J, Norwood DL, Mao LF, Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry 1991; 30:388-94.
92. Bjorge SM, Baillie TA. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Commun 1985; 132:245-52.
93. Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 1985; 145:69-76.
94. Gerbal-Chaloin S, Daujat M, Pascussi J-M, Pichard-Garcia L, Vilarem M-J, Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002; 277:209-17.
95. Ferguson SS, LeCluyse EL, Negishi M, Goldstein JA. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol 2002; 62:737-46.
96. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003; 1619:243-53.
97. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004; 308:495-501.
98. Chen Y, Kissling G, Negishi M, Goldstein JA. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 2005; 314:1125-33.
99. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 2004; 279:29295-301.
100. Jackson JP, Ferguson SS, Moore R, Negishi M, Goldstein JA. The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. Mol Pharmacol 2004; 65:1397-404.
101. Siemes H, Nau H, Schultze K, et al. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993; 34:332-46.
102. Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48:225-35.
103. Sugimoto T, Muro H, Woo M, Nishida N, Murakami K. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia 1996; 37:1200-3.
104. Hagley MT, Benak RL, Hulisz DT. Suspected cross-reactivity of enalapril- and captopril-induced hepatotoxicity. Ann Pharmacother 1992; 26:780-1.
105. Zannad F, Marie PY, Aliot E, Trechot P, Gilgenkrantz JM. Cytolytic hepatitis with captopril but not with enalapril. Cardiovasc Drugs Ther 1988; 1:669-70.
106. Alderman CP. Adverse effects of the angiotensinogen-converting enzyme inhbitors. Ann Pharmacother 1996; 30:55-61.
107. Keefe EB, Reis TC, Berland JE. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982; 27:701-4.
108. Tolman KG, Sannella JJ, Freston JW. Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 1974; 81:58-60.
109. Kóklú S, Yúksel O, Faruk Yolcu Ó, Arhan M, Altiparmak E. Cholestatic attack due to ampicilline and cross-reactivity to cefuroxime. Ann Pharmacother 2004; 38:1539-40.
110. Engel JJ, Vogt TR, Wilson DE. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 1975; 135:733-5.
111. Joshi PH, Conn HO. The syndrome of methoxyflurane-associated hepatitis. Ann Intern Med 1974; 80:395-401.
112. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathological study of 24 cases. Ann Intern Med 1983; 98:984-92.
113. Sigurdsen J, Hreidarsson AB, Thiodleifsson B. Enflurane hepatitis. A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 1985; 29:495-6.
114. Andrejak M, Davion T, Gineston JL, Capron JP. Cross hepatotoxicity between non-steroidal antiinflammatory drugs. Br Med J 1987; 295:180-1.
115. Larrey D, Rueff B, Pessayre D, et al. Cross hepatotoxicity between tricyclic antidepressants. Gut 1986; 27:726-7.
116. Remy AJ, Larrey D, Pageaux GP, Ribstein J, Ramos J, Michel H. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol 1995; 7:373-6.
117. Fernández-Checa JC, García-Ruiz C, Ookhtens M, Kaplowitz N. Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats. Tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. J Clin Invest 1991; 87:397-405.
118. Fernández-Checa JC, Hirano T, Tsukamoto H, Kaplowitz N. Mitochondrial glutathione depletion in alcoholic liver disease. Alcohol 1993; 10:469-75.
119. Tirmenstein MA, Nelson SD. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J Biol Chem 1989; 264:9814-9.
120. Zhao P, Kalhorn TF, Slattery JT. Selective mitochondrial glutathione depletion by ethanol enhances acetaminophen toxicity in rat liver. Hepatology 2002; 36:326-35.
121. Zhao P, Slattery JT. Effects of ethanol dose and ethanol withdrawal on rat liver mitochondrial glutathione: implication of potentiated acetaminophen toxicity in alcoholics. Drug Metab Dispos 2002; 30:1413-7.
122. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767-73.
123. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholic: a therapeutic misadventure. Ann Intern Med 1986; 104:399-404.
124. Cross FS, Long MW, Banner AS, Snider DE, Jr. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service cooperative therapy trial. Am Rev Respir Dis 1980; 122:349-53.
125. Langman G, Hall P, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16:1395-401.
126. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001; 50:S3-11.
127. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337:268-2691.
128. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57:485-91.
129. Kupferschmidt HHT, Riem Ha H, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58:20-8.
130. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996; 59:1025-30.
131. Soons PA, Vogels BAPM, Roosemalen MCM, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50:394-403.
132. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99:2545-53.
133. Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005; 33:644-8.
134. Hidaka M, Fujita K, Ogikubo T, et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004; 32:581-3.
135. Egashira K, Ohtani H, Itoh S, et al. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and p-glycoprotein. Drug Metab Dispos 2004; 32:828-33.
136. Honda Y, Ushigome F, Koyabu N, et al. Efffects of grapefruit juice and orange juice components on p-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004; 143:856-64.
137. Paine MF, Widmer WW, Hart HL, et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006; 83:1097-105.
138. Pessayre D, Wandscheer JC, Cobert B, et al. Additive effects of inducers and fasting on acetaminophen hepatotoxicity. Biochem Pharmacol 1980; 29:2219-23.
139. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. J Am Med Assoc 1994; 272:1845-50.
140. Price VF, Jollow DJ. Mechanism of decreased acetaminophen glucuronidation in the fasted rat. Biochem Pharmacol 1988; 37:1067-75.
141. Hong JY, Pan JM, Gonzalez FJ, Gelboin HV, Yang CS. The induction of a specific form of cytochrome P-450 (P-450j) by fasting. Biochem Biophys Res Commun 1987; 142:1077-83.
142. Soh Y, Rhee HM, Sohn DH, Song BJ. Immunological detection of CYP2E1 in fresh rat lymphocytes and its pretranslational induction by fasting. Biochem Biophys Res Commun 1996; 227:541-6.
143. Hu Y, Ingelman Sundberg M, Lindros KO. Induction mechanisms of cytochrome P450 2E1 in liver:interplay between ethanol treatment and starvation. Biochem Pharmacol 1995; 50:155-61.
144. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329:62-5.
145. Sanyal AJ, Mofrad PS, Contos MJ, et al. A randomized controlled pilot study of pioglitazone and vitaminm E versus vitamin E for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2:1107-15.
146. Chalasani NE, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and baseline liver enzymes. Am J Gastroenterol 2005; 100:1317-21.
147. Fernández-Villar A, Sopena B, Fernández-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8:1499-505.
148. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97:1198-203.
149. Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127:1304-11.
150. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495-9.
151. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis Carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776-82.
152. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003; 55:158-65.
153. O’Neil WM, MacArthur RD, Farrough MJ, et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 2002; 42:613-9.
154. Eck HP, Gmünder H, Hartmann M, Petzoldt D, Daniel V, Dröge W. Low concentrations of acidsoluble thiol (cysteine) in the blood plasma of HIV-1 infected patients. Biol Chem 1989; 370:101-8.
155. Buhl R, Holroyd KJ, Mastrangeli A, Cantin AM, Jaffe HA, Wells FB, Crystal RG. Systemic glutathione deficiency in symptom-free HIV seropositive individuals. Lancet 1989; 2:1294-8.
156. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, Park BK. Plasma cysteine deficiency and decreased reduction of nitrosomethoxazole with HIV infection. AIDS Res Hum Retroviruses 2000; 16:1929-38.
157. Rieder MJ, Krause R, Bird IA, Dekaban GA. Toxicity of sulfonamide-reactive metabolites in HIVinfected, HTLV-infected, and noninfected cells. J Acquir Immune Defic Syndr Hum Reterovirol 1995; 8:134-40.
158. Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167:180-5.
159. Ozick LA, Jacob L, Comer GM, et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients [see comments]. Am J Gastroenterol 1995; 90:1978-80.
160. Russell AS, Sturge RA, Smith MA. Serum transaminases during salicylate therapy. Br Med J 1971; 2:428-9.
161. Miller JJ, III, Weissman DB. Correlations between transaminase concentrations and serum salicylate concentration in juvenile rheumatoid arthritis. Arthritis Rheum 1976; 19:115-8.
162. Bernstein BH, Singsen BH, Koster King K, Hanson V. Aspirin-induced hepatotoxicity and its effect on juvenile rheumatoid arthritis. Am J Dis Child 1977; 131:659-63.
163. Iancu T. Serum transaminases and salicylate therapy. Br Med J 1972; 2:167.
164. Seaman WE, Plotz PH. Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers. Arthritis Rheum 1976; 19:155-60.
165. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981; 141:333-42.
166. Kromann-Andersen H. Adverse reactions during salazosulfapyridine (sulfasalazin) therapy in Denmark between 1968-1987. Ugeskrift For L*ger 1987; 149:3557-59.
167. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology 1995; 22:820-7.